Anti cancer controlled release formulation of containing interstitial hydrolytic agent
A technology of sustained-release injection and hydrolyzing agent, applied in the field of anti-cancer sustained-release agent, can solve the problems of enhanced tolerance of anti-cancer drugs, limited effective diffusion of drugs, obstacles to tumor chemotherapy, etc., to facilitate drug injection, improve interstitial fluid Conductivity, reducing the effect of complications
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Examples
Embodiment 1
[0131] Put 80mg of polyphenylpropane (p-CPP: 20:80 of sebacic acid (SA)) copolymer into a container, add 100ml of dichloromethane, dissolve and mix well, then add 10mg Paclitaxel and 10 mg of trypsin were re-shaken to prepare microspheres for injection containing 10% of paclitaxel and 10% of trypsin by spray-drying method. Then suspend the microspheres in physiological saline containing 15% mannitol to prepare the corresponding suspension-type sustained-release injection with a viscosity of 220cp-460cp (at 20°C-30°C). The drug release time of the slow-release injection in physiological saline in vitro is 10-15 days, and the drug release time in mice subcutaneous is about 20-30 days.
Embodiment 2
[0133] The method step of being processed into sustained-release injection is the same as in Example 1, but the difference is that the contained anticancer active ingredients and their weight percentages are:
[0134] (a) 5% pepsin, collagenase, streptokinase, glycosidase, hyaluronidase in combination with 25% paclitaxel or docetaxel;
[0135] (b) 20% collagenase, streptokinase, glycosidase or hyaluronidase and 10% carmustine, nimustine, bendamustine, garmustine, ramustine, fomo a combination of lomustine, homomustine, lomustine, methyllomustine, uramustine, samustine, semustine, streptozocin, or midazolamide; or
[0136] (c) 20% collagenase, streptokinase or hyaluronidase in combination with 20% vincristine, vinblastine, vinorelbine or vindesine.
[0137] The excipients used are: racemic polylactic acid, racemic polylactic acid / glycolic acid copolymer, monomethyl polyethylene glycol / polylactic acid, monomethyl polyethylene glycol / polylactic acid copolymer, polyethylene glyco...
Embodiment 3
[0139] Put 70 mg of polylactic acid (PLGA, 75:25) with a peak molecular weight of 65,000 into a container, add 100 ml of dichloromethane, dissolve and mix well, add 15 mg of collagenase and 15 mg of nimustine, re-shake and dry in vacuum Remove organic solvents. Freezing and pulverizing the dried drug-containing solid composition to make micropowder containing 15% collagenase and 15% nimustine, and then suspending in physiological saline containing 1.5% carboxymethylcellulose sodium to prepare the corresponding mixed Suspension-type sustained-release injection with a viscosity of 300cp-400cp (at 20°C-30°C). The drug release time of the slow-release injection in physiological saline in vitro is 10-15 days, and the drug release time in mice subcutaneous is about 20-30 days.
PUM
Property | Measurement | Unit |
---|---|---|
Viscosity | aaaaa | aaaaa |
Viscosity | aaaaa | aaaaa |
Viscosity | aaaaa | aaaaa |
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com